Background To evaluate belimumab (BLM) effectiveness in SLE patients from a Spanish multicenter registry.
Methods A longitudinal retrospective multicenter cohort including SLE patients treated with belimumab. Data collection at baseline, 6, 12 months and in the last visit available. Changes in SLEDAI-2K; LLDAS and DORIS-2021 states and response according to physician were compared between visits; also changes in damage and glucocorticoids used. T-test was used for numerical variables and the Fisher’s test for categorical variables.
Results 324 patients: 295 (91%) females with a mean (±SD) age of 42.4 (±12.9) years. Mean follow-up was 3,8 (±2.7) years and mean time with BLM was 2.7 (±2.4) years. Baseline mean SLEDAI-2K was 10.4 (±5.25). BLM was initiated with another DMARD in 67.9% of patients.
SLEDAI-2K significantly reduced in all visits. Rates of LLDAS, DORIS and clinical response according to physician criteria, significantly increased from baseline to the successive evaluations. Anti-dsDNA antibodies and inflammatory markers (ESR, CRP), significantly decreased over the time. (table 1).
107 (45,9%) patients discontinued GC. Mean (±SD) prednisone dose was significantly reduce over the visits: 12.3 (±12.16) and 4.7 (±3.7) mg/day at baseline and in the last visit, respectively (table 1). Median (IQR) SDI score at the end of the observation period did not change from baseline visit: 0 (0–1) and 0 (0–1) (p=0.97). No chanfes in the percentage of patients with damage between the beginning and the end of the study: 47.5% (n=152) and 45.6% (n=99), respectively.
Conclusions Our data confirm belimumab efficacy in real world, reducing clinical and serological activity in the short and medium-term. BLM leads to high rates of LLDAS and DORIS at 6 months, that continue increasing over time. BLM has an important GC sparing effect and prevents organ damage accrual. BLM is useful to achieve the therapeutic goals of a T2T strategy.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.